Clinical Trials

Endometrioid Endometrial Cancer

NCT03906669 2023-11-22

WinPro

200 enrolled

Breast Neoplasms

NCT06047184 2023-09-21

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

Phase 1 Unknown

106 enrolled

Advanced Breast Cancer

NCT00412022 2023-03-24

HOBOE

1,294 enrolled

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Phase 1/2 Unknown

59 enrolled

Breast Neoplasms

NCT04942899 2023-03-01

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

70 enrolled

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

73 enrolled

Breast Neoplasms

NCT05512416 2022-08-23

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

35 enrolled

Breast Neoplasms

NCT05512780 2022-08-23

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

30 enrolled

Other solid neoplasm

Solid Tumor

NCT05203562 2022-07-12

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Phase 2/3 Unknown

200 enrolled

Hydatidiform Mole, Gestational Trophoblastic Disease

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

434 enrolled

Advanced Breast Cancer

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

120 enrolled

HER2+ Breast Cancer

NCT03913234 2022-05-10

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Phase 1/2 Unknown

95 enrolled

Breast Neoplasms

NCT03625531 2022-04-05

A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS

1,100 enrolled

Polycystic Ovary Syndrome

NCT03633331 2021-10-15

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

93 enrolled 8 charts

Estrogen Receptor-positive Breast Cancer

NCT04407988 2021-10-13

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

86 enrolled

Breast Neoplasms

NCT04047758 2021-07-20

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

420 enrolled

Breast Neoplasms

NCT03966898 2021-06-02

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

426 enrolled

Advanced Breast Cancer

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Phase 1 Unknown

228 enrolled

Advanced Breast Cancer

NCT01758146 2020-03-04

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

412 enrolled

BreastOther

Breast Neoplasms, Obesity

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

3,697 enrolled

Breast Neoplasms

NCT04095390 2019-09-19

INPHASE

60 enrolled

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

20 enrolled

Breast Neoplasms

NCT04023292 2019-07-17

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

185 enrolled

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

250 enrolled

Breast Diseases, Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

7 enrolled

Breast Neoplasms

NCT03507465 2018-04-25

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Phase 2/3 Unknown

290 enrolled

Breast Neoplasms

NCT03497702 2018-04-13

NeoChAI

114 enrolled

Breast Neoplasms

NCT02214004 2018-02-15

HERAKLES

132 enrolled

Breast Neoplasms

NCT02769104 2018-01-09

ACCN

120 enrolled

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

58 enrolled

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02630485 2015-12-15

GLC

Phase NA Unknown

240 enrolled

Infertility, Polycystic Ovary Syndrome

NCT02551367 2015-09-16

LVCCFOROI

110 enrolled

Anovulation, Polycystic Ovary Syndrome

NCT02482740 2015-06-26

TGOG1005

44 enrolled

Uterine Cervical Neoplasms

NCT02188550 2015-05-19

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

20 enrolled

Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT01709370 2013-12-31

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

45 enrolled

ER Positive, HER2 Negative Breast Cancer

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

396 enrolled

Breast Neoplasms

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

100 enrolled

Breast Neoplasms

NCT01908556 2013-07-25

PreFace

Phase 4 Unknown

3,545 enrolled

is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.

NCT01116167 2013-05-20

Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine

Phase NA Unknown

660 enrolled

Polycystic Ovary Syndrome

NCT00687648 2009-06-17

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

70 enrolled

Breast Neoplasms

NCT00902954 2009-05-15

LEANEX

540 enrolled